Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

AIM Treatment options are limited in uterine cancer, leading to a poor prognosis. Overexpression of Wilms' tumor gene 1 (WT1), the highest ranked tumor antigen, is attractive for immunotherapy. PATIENTS AND METHODS Six pre-treated patients with uterine cancer received four weekly vaccines of autologous dendritic cells (DCs) electroporated with WT1 mRNA. Safety, feasibility and immunogenicity were assessed. In cases of response, patients received monthly booster vaccines. RESULTS The technique was feasible. One patient had a local allergic reaction. Three out of four Human Leucocyte Antigen-A2 (HLA-A2)-positive patients showed an oncological response; an enrichment of WT1-specific T-cells was observed in two of them. Two HLA-A2-negative patients did not show an oncological or an immunological response. CONCLUSION A first series of six patients with uterine cancer treated with WT1 mRNA-electroporated DCs is presented herein. Oncological and immunological responses were observed and are supportive for further research.

[1]  J. Sakamoto,et al.  WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial , 2013, Journal of Cancer Research and Clinical Oncology.

[2]  J. Menten,et al.  Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial , 2012, Cancer Immunology, Immunotherapy.

[3]  Z. Berneman,et al.  Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. , 2012, The oncologist.

[4]  B. van Calster,et al.  Wilms Tumor Gene 1 (WT1) is a Prognostic Marker in High-Grade Uterine Sarcoma , 2010, International Journal of Gynecologic Cancer.

[5]  F. Amant,et al.  Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. , 2010, Anticancer research.

[6]  H. Goossens,et al.  Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination , 2010, Proceedings of the National Academy of Sciences.

[7]  G. Coukos,et al.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. , 2010, Gynecologic oncology.

[8]  D. Timmerman,et al.  Clinical management of uterine sarcomas. , 2009, The Lancet. Oncology.

[9]  J. Sakamoto,et al.  Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. , 2009, Anticancer research.

[10]  S. Van Cauter,et al.  Dendritic Cell Therapy of High‐Grade Gliomas , 2009, Brain pathology.

[11]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[12]  G. Shurin,et al.  Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism1 , 2009, The Journal of Immunology.

[13]  E. Thiel,et al.  A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.

[14]  P. Neven,et al.  Wilms' tumor gene 1 (WT1) in endometrial carcinoma. , 2008, Gynecologic oncology.

[15]  R. Sciot,et al.  Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[16]  I. Kawase,et al.  WT1 peptide vaccine for the treatment of cancer. , 2008, Current opinion in immunology.

[17]  G. Schuler,et al.  Effective Clinical-scale Production of Dendritic Cell Vaccines by Monocyte Elutriation Directly in Medium, Subsequent Culture in Bags and Final Antigen Loading Using Peptides or RNA Transfection , 2007, Journal of immunotherapy.

[18]  M. Minden,et al.  A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.

[19]  G. Bepler,et al.  Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[20]  F. Brasseur,et al.  Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines , 2005, Gene Therapy.

[21]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[22]  J. Ceuppens,et al.  Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells , 2005, Cancer Immunology, Immunotherapy.

[23]  C. van Broeckhoven,et al.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. , 2001, Blood.

[24]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.